Premium
The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria
Author(s) -
Danis Martin,
Bricaire François
Publication year - 2003
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1046/j.1472-8206.2003.00165.x
Subject(s) - malaria , atovaquone , artemether , plasmodium falciparum , lumefantrine , proguanil , artemether/lumefantrine , drug , medicine , drug resistance , pharmacology , intensive care medicine , artemisinin , biology , immunology , microbiology and biotechnology
Malaria is a leading cause of morbidity and mortality in developing countries. Selection of mutant Plasmodium falciparum malaria strains under drug pressure has led to the development of drug resistance. There is a pressing need for effective, safe, practicable drug combinations that hve lower selection pressure. A review of the mein drug combinations, which are recently registered or are still under development, was undertaken, with special attention to the atovaquone–proguanil and artemether–lumefantrine combination.